ArticlePediatric cardiology2026
Cardioneuromodulation for Recurrent Malignant Neurocardiogenic Syncope in Pediatric Patients: Results from a Tertiary Center.
Article in Pediatric cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant neurocardiogenic syncope (MNS) is defined as recurrent syncope with minimal prodromes associated with significant prolonged asystole during head-up tilt test (HUTT). Although cardioneuromodulation (CNM) is an emerging therapy for cardioinhibitory reflex syncope and other functional bradyarrhythmias and is increasingly considered an alternative to cardiac pacing in selected adult patients, evidence for its use in children remains limited. This study aims to describe the procedural characteristics and clinical outcomes of CNM in pediatric patients with MNS and to identify the clinical profile of those most likely to benefit from CNM. This is a prospective observational single-arm cohort. All pediatric patients with recurrent traumatic syncope and HUTT-documented asystole (≥ 15 seconds) undergoing CNM were enrolled. Baseline clinical features, HUTT findings, procedural data, acute endpoints, complications, and follow-up outcomes were collected. All patients underwent CNM using a right atrial-only approach, targeting right-sided ganglionated plexi using anatomical and electrogram guidance. Eight patients (50% female; mean age 13 ± 2.5 years) with a high burden of traumatic reflex syncope were enrolled in this study. All procedures were completed without major complications. After ablation, an implantable loop recorder (ILR) was inserted in all patients for continuous rhythm surveillance. During a short-term follow-up (6 ± 3 months), all patients experienced marked reduction in syncope burden with no further traumatic recurrences (from a mean of 2 episodes/month to 0 episodes at 6 ± 3 months); ILR monitoring showed no prolonged asystole. In this small pediatric cohort, CNM was safe, feasible, and associated with favorable short-term clinical and rhythm outcomes. Larger pediatric studies with standardized selection criteria and longer follow-up are needed to define efficacy and durability.
Indexed as
Identifiers
42841939What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.